Association between anti-inflammatory interleukin-10 and executive function in African American women at risk for Alzheimer’s disease

A Pilot randomized clinical trial of adapted tango to improve cognition and psychosocial function in African American women with family history of Alzheimer's disease (ACT trial)

“…Recent studies [13] , [14] , [15] , [16] , [17] , [63] , [64] demonstrate that increased blood-based inflammatory biomarkers are correlated to the development of AD, and that chronic inflammation imparts a risk of cognitive decline. As blood-based biomarkers represent a low-invasive and low-cost screen tool to monitor cerebral inflammatory activity, these analytes are ideal for evaluation in an asymptomatic population.…”

“…It has been well documented that peripheral inflammation is implicated in cognitive decline and AD [13] , [14] , [15] , [16] , [17] . Recent reports suggest that systemic inflammation correlates to AD biomarkers in the brain, and some inflammatory markers may be distinctly upregulated within B/AAs [3] and AD informal family caregivers [18] .…”

Health disparities in aging: Improving dementia care for Black women

“…Recent studies have focused on biological mechanisms involved in both stress and ADRD, such as inflammation and oxidative damage pathways. One pilot study demonstrated an association between high interleukin-10 levels and impaired executive function but yielded mixed results on cognitive measures ( Patel et al, 2020 ). Reduced AD risk in Black women that utilize statins has also been observed, possibly supporting that metabolic dysfunction and inflammation act as primary biological drivers for increased ADRD incidence in Black women ( Zissimopoulos et al, 2017 ).…”

Transcript levels in plasma contribute substantial predictive value as potential Alzheimer's disease biomarkers in African Americans

“…A few studies have evaluated in an AA cohort the use of plasma proteins or metabolites as a fluid biomarker for AD, but none of these have evaluated plasma cf-mRNAs. 9 , 39 , 40 , 41 , 42 , 43 Future studies should systematically evaluate the biomarker potential of all transcripts detectable in plasma in diverse populations and incorporate these plasma cf-RNAs into a biomarker panel along with plasma levels of proteins and metabolites that have been shown to effectively discriminate AD from CU and other types of dementias, such as Aß42/Aß40 ratio and p-tau, in order to achieve greater discriminatory potential and add theragnostic value.…”